BioSignal Scientific Trust StandardContinuously reviewed using the BioSignal Scientific Evaluation Framework
View MethodologyNAD+
Nicotinamide Adenine Dinucleotide
NAD+ is a fundamental cellular coenzyme involved in energy production, DNA repair, and cellular signaling, while evidence for NAD+-boosting therapies remains promising but incomplete.
If you're here because…
Jump to the part of this record most relevant to your question. These are guides to information, not recommendations.
How confident is BioSignal?
One overall judgement, then the independent dimensions behind it — each on the same scale.
BioSignal's overall confidence is measured: NAD+'s core biology is well established, but the evidence that boosting NAD+ delivers meaningful clinical benefits in healthy people remains limited.
Biological Role
High confidenceNAD+'s role as a coenzyme in energy metabolism, DNA repair, and signaling is well established in foundational biochemistry.
Human Evidence
Moderate confidenceHuman studies exist for several NAD+-boosting precursors, but many are small, short, or measure biomarkers rather than clinical outcomes.
Supplement Benefit
Moderate confidencePrecursors such as NR and NMN can raise NAD+ levels; whether that translates into consistent clinical benefit is still being established.
Safety Confidence
Moderate confidenceShort-term use of common precursors appears generally well tolerated in trials to date; long-term human safety data are limited.
Research Activity
HighNAD+ is an active, fast-moving research area spanning aging, metabolism, and neuroscience.
BioSignal Bottom Line
The honest shape of the evidence in five parts — what we know, what we think, what we don't, what's being studied, and what could change our view.
What We Know
NAD+ is essential for cellular energy metabolism, mitochondrial function, DNA repair, and cellular signaling.
What We Think
Maintaining healthy NAD+ metabolism appears biologically important, but clinical benefits from NAD+-boosting strategies vary by intervention and remain under study.
What We Don't Know
It remains unclear whether increasing NAD+ produces meaningful long-term healthspan or longevity benefits in healthy humans.
Active Research
Current research is exploring NAD+ biology in aging, mitochondrial health, metabolic disease, neurodegeneration, and exercise physiology.
What Could Change Our Mind
Large, long-term randomized human trials showing meaningful clinical outcomes would materially change BioSignal's confidence.
Does it work?
The most common public claims about NAD+, each weighed against the current evidence — what's supported, what's mixed, and what isn't established.
“NAD+ improves energy”
Human evidence suggests possible improvements in selected metabolic measures, but consistent improvements in subjective energy have not been established.
Mixed EvidenceModerate confidence“NAD+ slows aging”
Preclinical work links NAD+ to aging biology, but there is no established evidence that supplementation slows aging in humans.
Not EstablishedLimited evidence“NAD+ improves cognition”
Human cognitive outcomes have been examined only in small or preliminary studies; an effect is not established.
Insufficient EvidenceLimited evidence“NAD+ repairs DNA”
NAD+ is a required substrate for DNA-repair enzymes — its mechanistic role is well established. This does not, by itself, imply a clinical benefit from supplementation.
SupportedHigh confidence“NAD+ improves exercise performance”
Trials in athletic and older populations report inconsistent effects on performance, with no clear established benefit.
Mixed EvidenceModerate confidence“NAD+ extends lifespan”
Lifespan extension from raising NAD+ has been observed in some model organisms but has not been demonstrated in humans.
Not EstablishedLimited evidence“NAD+ improves recovery”
Some studies report changes in recovery-related markers, but consistent clinical benefit is not established.
Mixed EvidenceModerate confidence
Practical takeaways
The current evidence, distilled to five points.
- NAD+ is essential for cellular energy production and DNA repair.
- Its core biology is well established.
- Oral precursors can raise NAD+ biomarkers in humans.
- Long-term clinical benefits in healthy people remain uncertain.
- Larger, longer human trials are needed to draw firm conclusions.
Dosages used in human studies
The doses researchers have actually studied — summarised for understanding, not as guidance.
| Population | Intervention | Dose | Duration | Primary Outcome | Study Notes |
|---|---|---|---|---|---|
| Healthy adults | Oral nicotinamide riboside (NR) | ~250–1,000 mg/day | Weeks to a few months | Blood NAD+ levels (biomarker) | Prototype — raises NAD+ biomarkers; clinical outcomes vary |
| Older adults | Oral nicotinamide mononucleotide (NMN) | ~250–900 mg/day | Several weeks | NAD+ biomarkers; physical measures | Prototype — early-stage human research |
| Clinical / varied | Intravenous NAD+ | Varies widely | Single or repeated sessions | Tolerability; exploratory endpoints | Prototype — limited controlled data |
| Athletes | Oral precursors | Study-dependent | Days to weeks | Performance / recovery markers | Prototype — mixed results |
BioSignal Note. These protocols summarise doses used in published human research. They are provided for educational purposes and should not be interpreted as treatment recommendations.
What kinds of evidence exist?
A high-level view of the current evidence landscape by category. Counts are intentionally unquantified until sourcing is complete.
- Prototype
Human Studies
Controlled and observational studies in people. Pending the Scientific Evaluation Workflow.
- Prototype
Mechanistic Evidence
Biochemical and cellular work establishing NAD+'s roles. Pending sourcing.
- Prototype
Preclinical Evidence
Animal and in-vitro studies of NAD+ biology and precursors. Pending sourcing.
- Prototype
Systematic Reviews
Reviews and meta-analyses synthesizing the literature. Pending sourcing.
- Prototype
Active Research
Ongoing and recently registered studies. Pending sourcing.
How did we get here?
The chronological arc of how scientific understanding evolved, from foundational biology to current clinical research.
Foundational Biology
Decades of biochemistry established NAD+ as a central coenzyme in metabolism and redox reactions.
NAD+ and Aging Research
Research linked declining NAD+ levels with aspects of aging in preclinical models.
Human Precursor Studies
Early human trials began testing whether oral precursors can raise NAD+ levels safely.
Current Clinical Research
Ongoing studies examine clinical outcomes across metabolic, neurological, and aging-related contexts.
Understand the science in detail
Deeper explanations and FAQs — definitions, mechanisms, and how the science is studied. Open any question to go further.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It acts as a central carrier of electrons in metabolism and as a substrate for enzymes involved in DNA repair and cellular signaling. In short, it is one of the molecules that keeps basic cellular machinery running.
Because NAD+ participates in energy production, mitochondrial function, and DNA-repair signaling, healthy NAD+ metabolism is considered important for normal cell function. This biological centrality is why NAD+ has become a focus of aging and metabolic research — though biological importance alone does not establish that supplementation produces clinical benefit.
NAD+ research spans several layers: biochemical and cell studies establish its molecular roles; animal models explore the effects of raising or lowering it; and human trials typically measure NAD+ levels in blood or tissue after giving precursors, sometimes alongside functional or clinical measures. Because methods and measurements differ between studies, results are not always directly comparable.
Declines in NAD+ levels with age have been reported in preclinical models and some human tissues. The extent, consistency, and functional significance of these declines in healthy people are still being characterized, and measurement methods vary between studies.
NAD+ itself is usually not taken directly; instead, precursors are used. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are oral precursors the body converts toward NAD+. Intravenous NAD+ delivers the molecule directly but has limited high-quality comparative human evidence. Which precursor or route is most effective for a given outcome is not established.
Studies vary in population, dose, duration, the precursor used, and the outcomes measured — and many are small or short. Raising a biomarker like NAD+ does not automatically translate into a change people can feel or that appears on clinical measures. These differences help explain why findings across studies can look inconsistent.
Is it safe?
What is reasonably known, kept clearly separate from what remains uncertain or warrants caution.
What's reasonably known
Known Safety Profile
Common NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have been studied in short-term human trials and are generally reported as well tolerated at the doses studied.
Commonly Reported Issues
- Mild gastrointestinal discomfort
- Nausea
- Headache
- Flushing (more associated with high-dose niacin than with NR or NMN)
What's uncertain or warrants caution
Long-Term Unknowns
The long-term safety of sustained NAD+ elevation in healthy people has not been established. Effects over years of continuous use remain unknown.
Populations Requiring Caution
- People who are pregnant or breastfeeding
- People with active or prior cancer (NAD+ metabolism intersects with cell-growth pathways)
- People taking prescription medications
- Children and adolescents
Evidence Limitations
Most safety data come from small, short-duration studies. The absence of reported harm is not the same as proven long-term safety.
Educational information only. Not medical advice.
What do scientists agree on?
Where the science is settled, where it is genuinely contested, and where it is still open.
Broad Agreement
Strongly supported by consistent evidence.
- NAD+ is essential to core cellular metabolism and energy production.
- NAD+ is a required substrate for DNA-repair and signaling enzymes.
- Oral precursors (NR, NMN) can raise NAD+ biomarkers in humans.
Active Debate
Evidence is mixed or experts disagree.
- Whether raising NAD+ biomarkers produces consistent clinical benefits.
- Which precursor or route (oral vs intravenous) is most effective.
- The functional significance of age-related NAD+ decline in humans.
Unknowns
Important questions that remain unanswered.
- Whether NAD+ strategies affect long-term healthspan or lifespan in healthy people.
- Optimal dosing, and which populations benefit most.
- The long-term safety of sustained NAD+ elevation.
What remains unknown?
The questions the current evidence cannot yet answer — and what it would take to answer them.
- Do increases in NAD+ biomarkers translate into outcomes people can feel or measure clinically?
- Is there a meaningful long-term healthspan or longevity benefit in healthy humans?
- Which precursor, dose, and route — if any — is most effective?
- What are the effects of years of continuous use?
Large, long-term randomized human trials showing meaningful clinical outcomes would materially change BioSignal's confidence.
Connected Science
How this record connects to the wider science. Each node will open its own Signal Record as the graph grows.
The beginning of the BioSignal Knowledge Graph — interactive graph view coming in a future sprint.
Evidence & References
References are structured Evidence Cards, not a flat bibliography — and are added only through a review process.
References will be added through the BioSignal Scientific Evaluation Workflow before publication. The cards below show the structure each sourced study will follow.
- Source
- Publication
- Population
- Sample size
- Duration
- Primary findings
- Limitations
- Confidence contribution
- Source
- Publication
- Population
- Sample size
- Duration
- Primary findings
- Limitations
- Confidence contribution
Version History
Every Signal Record evolves as the science evolves. Changes are tracked here.
Prototype Signal Record created for product development. Future versions will track scientific updates, evidence changes, and review history.